• Download mobile app
25 May 2024, Edition - 3238, Saturday

Trending Now

  • The film where Bobby Simha and Yogi Babu are scheduled to act together is titled ‘Nonviolence’.
  • NTK leader Seeman yields a challenge. Vows to dismantle party if BJP gets more votes than his party in the constituencies that they are contesting .
  • EPS condemns Kerala govt for having sent a letter to Centre seeking to construct a new dam after demolishing the Mullaiperiyar Dam.
  • Schools to reopen on June 6 for students from Class 1 to XII in TN : Education Department

Coimbatore

Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

Covai Post Network

Share

Coimbatore : Glenmark Pharmaceuticals Limited (Glenmark Pharma), a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widely-used Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita® DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes. On the occasion of the launch, Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated, “India has the second-largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1C ), beta cell dysfunction, which impairs insulin secretion, along with other co-morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers. Being a leader in treating diabetes, we are proud to introduce Zita® DM, a novel and affordable anti-diabetic drug, which helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events. With this robust profile, we are positive Zita® DM will facilitate patient adherence to chronic diabetes treatments.” Glenmark’s Zita® portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita® DM, Zita® the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.

Subscribe To Our Newsletter

COIMBATORE WEATHER